Autologous CD19-targeting CAR T cells

BIOLOGICAL2 trials

Sponsors

Hebei Senlang Biotechnology Inc., Ltd.

Conditions

Acute Lymphocytic LeukemiaB-Cell LeukemiaB-Cell Lymphoma

Phase 1

CAR T Cells for Refractory B Cell Malignancy

Hebei Senlang Biotechnology Inc., Ltd.B-Cell Leukemia, B-Cell Lymphoma

Start: 2016-06-30End: 2021-06-30Target: 10Updated: 2017-04-28

Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia

Hebei Senlang Biotechnology Inc., Ltd.Acute Lymphocytic Leukemia

Start: 2019-01-02End: 2022-01-31Target: 20Updated: 2021-01-20

Related Papers

Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells <i>in vivo</i>.

2021-03-1344 citations

Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)

BMJ Open2020-02-0149 citations

Surface Density of CAR Molecules May Modulate the Kinetics of CAR-T Cells In Vivo

Blood2019-11-13

Preliminary results of phase I/II study of SENL-B19 chimeric antigen receptor T cell therapy in pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r-ALL)

Annals of Oncology2018-10-011 citations